HAL (France)
open access
Stoichiometric Antibody–Polymer–Drug Conjugate for Effective Low-Dose Treatment of Breast Cancer
In the past two decades, antibody–drug conjugates (ADCs) have emerged as highly effective targeted therapeutics against cancers. One current path to improve ADCs is to increase the amount of cytotoxic payload delivered to cancer cells by conjugating antibodies with a soluble polymer bearing several
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.#452916
- From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates#922939
- Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.#433837
- Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.#122713
- Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer#1349653
Record · ID 1203339
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive